Nilotinib in patients with metastatic melanoma harboring KIT gene aberration (Q39688974)

14 September 2017

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration (English)

1 reference

14 September 2017

0 references

1 reference

2

Kyoung Mee Kim

1 reference

14 September 2017

Jin Hyun Cho

1

1 reference

14 September 2017

Miyeon Kwon

series ordinal

3

1 reference

14 September 2017

Jung Han Kim

series ordinal

4

1 reference

14 September 2017

Jeeyun Lee

series ordinal

5

1 reference

14 September 2017

9 November 2011

1 reference

Investigational New Drugs

14 September 2017

1 reference

14 September 2017

30

1 reference

14 September 2017

5

1 reference

14 September 2017

2008-2014

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-011-9763-9

14 September 2017

0 references

cites work

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

KIT amplification and gene mutations in acral/mucosal melanoma in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Large-scale analysis of KIT aberrations in Chinese patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9763-9

Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians

21 January 2018

1 reference

12 December 2020

[Construction and screening of the human phage antibody library from a patient with melanoma].

1 reference

12 December 2020

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

1 reference

12 December 2020

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

12 December 2020

10.1007/S10637-011-9763-9

Identifiers

DOI

1 reference

14 September 2017

1 reference